Sermorelin

Sermorelin is a synthetic peptide corresponding to the biologically active 1-29 fragment of human growth-hormone-releasing hormone, GHRH(1-29)-NH₂ — the shortest fragment that retains the full GH-releasing activity of the native 44-residue hormone. It serves as a reference GHRH-receptor agonist across endocrine research. [1]

Structure-activity studies systematically mapped which residues of GHRH(1-29)-NH₂ are essential for receptor binding and activation. [1] Unlike the engineered long-acting analogues CJC-1295 and tesamorelin, unmodified sermorelin is rapidly degraded (in part by DPP-4) and therefore has a short circulating half-life — a property that makes it a useful tool for studying the native, short-pulse GHRH signal rather than sustained stimulation.

As a GHRH-receptor agonist on pituitary somatotrophs, sermorelin drives synthesis and release of growth hormone. In human “clamp” studies, continuous GHRH(1-29)NH₂ amplified GH pulse amplitude while preserving pulse timing, supporting a role for GHRH in GH synthesis and the replenishment of stored GH pools, with somatostatin tone shaping the timing of pulses. [2]

GHRH and its receptor have been studied well beyond the pituitary. In-vitro work reported GHRH(1-29)NH₂ effects on proliferation and VEGF secretion in a human neuroendocrine tumour cell line, [3] and a wider body of research on GHRH-receptor agonists and antagonists has examined their signalling in diverse peripheral tissues, illustrating that GHRH biology extends past simple GH release. [4]

Sermorelin's history as an endocrine research tool — and, historically, a diagnostic agent for GH-axis testing — does not extend to the research-grade material offered here. This product is supplied strictly for in-vitro and laboratory study by qualified professionals; it is not formulated, dosed, or authorised for use in humans or animals, and nothing here constitutes a therapeutic claim.